Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cobalt Laboratories has settled patent litigation with GlaxoSmithKline relating to sumatriptan succinate tablets, the generic version of GSK's Imitrex tablets.
Subscribe to our email newsletter
The terms of the settlement, which remain subject to government review, provide that Cobalt may distribute a generic version of sumatriptan succinate tablets in the US with an expected launch date early in the first quarter, 2009.
Additional terms of the settlement agreement were not disclosed.
GlaxoSmithKline's Imitrex tablets, which are indicated for the acute treatment of migraine attacks in adults, had US sales of $890 million for the 12 month period ending June.
Cobalt Laboratories is the US subsidiary of Arrow Pharmaceuticals.